(ARWR) Arrowhead Pharmaceuticals - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US04280A1007

Plozasiran, Zodasiran, ARO-DIMER-PA, ARO-PNPLA3, ARO-INHBE

Biotechnology
Market Cap in USD: 8,971m
IPO / Inception: 1993-06-16
12m vs SPY: 196%

EPS (Earnings per Share)

EPS (Earnings per Share) of ARWR over the last years for every Quarter: "2020-12": -0.2, "2021-03": -0.26, "2021-06": -0.29, "2021-09": -0.61, "2021-12": -0.6, "2022-03": 0.41, "2022-06": -0.68, "2022-09": -0.81, "2022-12": -0.39, "2023-03": 0.45, "2023-06": -0.96, "2023-09": -1.02, "2023-12": -1.24, "2024-03": -1.02, "2024-06": -1.38, "2024-09": -1.37, "2024-12": -1.39, "2025-03": 2.75, "2025-06": -1.26, "2025-09": -0.11, "2025-12": 0,
EPS CAGR: -6.28%
EPS Trend: 3.2%
Last SUE: -0.09
Qual. Beats: 0

Revenue

Revenue of ARWR over the last years for every Quarter: 2020-12: 21.303, 2021-03: 32.811, 2021-06: 45.891, 2021-09: 38.283, 2021-12: 27.439, 2022-03: 151.805, 2022-06: 32.412, 2022-09: 31.575, 2022-12: 62.546, 2023-03: 146.267, 2023-06: 15.825, 2023-09: 16.097, 2023-12: 3.551, 2024-03: 0, 2024-06: 0, 2024-09: 23.589, 2024-12: 2.5, 2025-03: 542.709, 2025-06: 27.767, 2025-09: 256.472, 2025-12: null,
Rev. CAGR: 81.49%
Rev. Trend: -9.4%
Last SUE: 0.44
Qual. Beats: 0

Dividends

Currently no dividends paid
Risk via 5d forecast
Volatility 63.5%
Value at Risk 5%th 93.7%
Relative Tail Risk -10.36%
Reward TTM
Sharpe Ratio 2.09
Alpha 216.24
CAGR/Max DD 0.33
Character TTM
Hurst Exponent 0.555
Beta 1.759
Beta Downside 1.552
Drawdowns 3y
Max DD 75.86%
Mean DD 34.90%
Median DD 35.63%

Description: ARWR Arrowhead Pharmaceuticals January 13, 2026

Arrowhead Pharmaceuticals (NASDAQ:ARWR) focuses on RNA-interference (RNAi) therapeutics for hard-to-treat diseases in the U.S. Its lead pipeline features Plozasiran (apoC-III) and Zodasiran (ANGPTL3), both in Phase 3 trials, alongside a suite of early-stage RNAi candidates targeting metabolic and inflammatory pathways (e.g., ARO-DIMER-PA, ARO-PNPLA3, ARO-INHBE, ARO-ALK7, ARO-RAGE, ARO-MAPT, ARO-C3, ARO-CFB). The company leverages partnership agreements with GlaxoSmithKline, Takeda, Amgen, and Sarepta to co-develop and commercialize its assets.

As of the latest 10-Q, Arrowhead reported a cash position of roughly $560 million, providing a runway of about 18 months at current burn rates; its market capitalization hovers near $3 billion, and recent Phase 3 interim data for Plozasiran showed a 30 % reduction in triglycerides, a key efficacy signal that could unlock a multi-billion-dollar market if FDA approval is achieved.

The RNAi sector is experiencing rapid growth, driven by the FDA’s expanding acceptance of gene-silencing modalities (e.g., approvals of Alnylam’s Onpattro and GIVLAARI) and a projected CAGR of 20 % through 2030, which underpins strong investor interest and higher valuation multiples for companies with late-stage pipelines.

For a deeper dive into Arrowhead’s valuation dynamics and scenario analysis, you might explore the detailed model on ValueRay.

Piotroski VR‑10 (Strict, 0-10) 5.5

Net Income (-1.63m TTM) > 0 and > 6% of Revenue (6% = 49.8m TTM)
FCFTA 0.11 (>2.0%) and ΔFCFTA 64.34pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 91.04% (prev 2182 %; Δ -2091 pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA 0.13 (>3.0%) and CFO 179.6m > Net Income -1.63m (YES >=105%, WARN >=100%)
Net Debt (166.2m) to EBITDA (100.6m) ratio: 1.65 <= 3.0 (WARN <= 3.5)
Current Ratio 4.86 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (135.7m) change vs 12m ago 11.24% (target <= -2.0% for YES)
Gross Margin 97.89% (prev 0.0%; Δ 97.89pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 65.70% (prev 2.38%; Δ 63.32pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio 0.93 (EBITDA TTM 100.6m / Interest Expense TTM 89.4m) >= 6 (WARN >= 3)

Altman Z'' -1.75

(A) 0.55 = (Total Current Assets 950.6m - Total Current Liabilities 195.5m) / Total Assets 1.39b
(B) -1.17 = Retained Earnings (Balance) -1.63b / Total Assets 1.39b
warn (B) unusual magnitude: -1.17 — check mapping/units
(C) 0.07 = EBIT TTM 83.1m / Avg Total Assets 1.26b
(D) -1.85 = Book Value of Equity -1.63b / Total Liabilities 881.9m
Total Rating: -1.75 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 54.24

1. Piotroski 5.50pt
2. FCF Yield 1.63%
3. FCF Margin 18.91%
4. Debt/Equity 1.57
5. Debt/Ebitda 1.65
6. ROIC - WACC (= -2.60)%
7. RoE -0.38%
8. Rev. Trend -9.36%
9. EPS Trend 3.19%

What is the price of ARWR shares?

As of January 17, 2026, the stock is trading at USD 65.91 with a total of 1,852,762 shares traded.
Over the past week, the price has changed by +1.92%, over one month by -3.21%, over three months by +73.47% and over the past year by +249.97%.

Is ARWR a buy, sell or hold?

Arrowhead Pharmaceuticals has received a consensus analysts rating of 4.13. Therefore, it is recommended to buy ARWR.
  • Strong Buy: 7
  • Buy: 3
  • Hold: 5
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the ARWR price?

Issuer Target Up/Down from current
Wallstreet Target Price 77.9 18.2%
Analysts Target Price 77.9 18.2%
ValueRay Target Price 69.3 5.2%

ARWR Fundamental Data Overview January 10, 2026

P/E Forward = 111.1111
P/S = 10.8154
P/B = 19.1634
P/EG = -1.32
Revenue TTM = 829.4m USD
EBIT TTM = 83.1m USD
EBITDA TTM = 100.6m USD
Long Term Debt = 214.9m USD (from longTermDebt, last quarter)
Short Term Debt = 40.0m USD (from shortLongTermDebt, last quarter)
Debt = 733.7m USD (from shortLongTermDebtTotal, last fiscal year)
Net Debt = 166.2m USD (from netDebt column, last quarter)
Enterprise Value = 9.62b USD (8.97b + Debt 733.7m - CCE 88.7m)
Interest Coverage Ratio = 0.93 (Ebit TTM 83.1m / Interest Expense TTM 89.4m)
EV/FCF = 61.29x (Enterprise Value 9.62b / FCF TTM 156.9m)
FCF Yield = 1.63% (FCF TTM 156.9m / Enterprise Value 9.62b)
FCF Margin = 18.91% (FCF TTM 156.9m / Revenue TTM 829.4m)
Net Margin = -0.20% (Net Income TTM -1.63m / Revenue TTM 829.4m)
Gross Margin = 97.89% ((Revenue TTM 829.4m - Cost of Revenue TTM 17.5m) / Revenue TTM)
Gross Margin QoQ = 100.0% (prev 77.59%)
Tobins Q-Ratio = 6.94 (Enterprise Value 9.62b / Total Assets 1.39b)
Interest Expense / Debt = 2.96% (Interest Expense 21.7m / Debt 733.7m)
Taxrate = 21.0% (US default 21%)
NOPAT = 65.6m (EBIT 83.1m * (1 - 21.00%))
Current Ratio = 4.86 (Total Current Assets 950.6m / Total Current Liabilities 195.5m)
Debt / Equity = 1.57 (Debt 733.7m / totalStockholderEquity, last quarter 466.1m)
Debt / EBITDA = 1.65 (Net Debt 166.2m / EBITDA 100.6m)
Debt / FCF = 1.06 (Net Debt 166.2m / FCF TTM 156.9m)
Total Stockholder Equity = 431.1m (last 4 quarters mean from totalStockholderEquity)
RoA = -0.13% (Net Income -1.63m / Total Assets 1.39b)
RoE = -0.38% (Net Income TTM -1.63m / Total Stockholder Equity 431.1m)
RoCE = 12.86% (EBIT 83.1m / Capital Employed (Equity 431.1m + L.T.Debt 214.9m))
RoIC = 9.04% (NOPAT 65.6m / Invested Capital 725.7m)
WACC = 11.64% (E(8.97b)/V(9.70b) * Re(12.40%) + D(733.7m)/V(9.70b) * Rd(2.96%) * (1-Tc(0.21)))
Discount Rate = 12.40% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 12.40%
[DCF Debug] Terminal Value 70.36% ; FCFF base≈156.9m ; Y1≈193.5m ; Y5≈329.6m
Fair Price DCF = 21.69 (EV 3.18b - Net Debt 166.2m = Equity 3.01b / Shares 139.0m; r=11.64% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 3.19 | EPS CAGR: -6.28% | SUE: -0.09 | # QB: 0
Revenue Correlation: -9.36 | Revenue CAGR: 81.49% | SUE: 0.44 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.89 | Chg30d=+0.190 | Revisions Net=-3 | Analysts=7
EPS current Year (2026-09-30): EPS=-3.46 | Chg30d=-0.295 | Revisions Net=-4 | Growth EPS=-34490.0% | Growth Revenue=-53.0%
EPS next Year (2027-09-30): EPS=-4.54 | Chg30d=-0.039 | Revisions Net=-4 | Growth EPS=-31.2% | Growth Revenue=-29.0%

Additional Sources for ARWR Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle